Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo

Executive Summary

Head of U.S. clinical development program is David Richards, MD, who holds the title of senior VP-medical operations. Richards assumed that position last fall moving over from Glaxo Group Research, where he was a medical director. "The Pink Sheet" previously reported incorrectly that Peter Wise, MD, is head of the Glaxo, a medical director. "The Pink Sheet" previously reported incorrectly that Peter Wise, MD, is head of the Glaxo, Inc. clinical programs. Wise holds the title of senior VP-medical marketing and heads a research group that develops new uses for already marketed products as well as line extensions, dosage regimens, and new market niches.

You may also be interested in...



‘No Turning Back’ On Regulatory Changes at UK MHRA

The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.

Warning Letter Roundup & Recap – 22 September 2020

No device-related warning letters were released by the US FDA the week of 22 September.

Neuraxpharm Snapped Up By Private Equity In Europe’s Largest Deal

Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel